The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
Open accessAbstract
Tumors use several strategies to evade the host immune response, including creation of an immune-suppressive and hostile tumor environment. Tissue hypoxia due to inadequate blood supply is reported to develop very early during tumor establishment. Hypoxic stress has a strong impact on tumor cell biology. In particular, tissue hypoxia contributes to therapeutic resistance, heterogeneity and progression. It also interferes with immune plasticity, promotes the differentiation and expansion of immune-suppressive stromal cells, and remodels the metabolic landscape to support immune privilege. Therefore, tissue hypoxia has been regarded as a central factor for tumor aggressiveness and metastasis. In this regard, manipulating host–tumor interactions in the context of the hypoxic tumor microenvironment may be important in preventing or reverting malignant conversion. We will discuss how tumor microenvironment-driven transient compositional tumor heterogeneity involves hypoxic stress. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of conventional therapies as well as cancer immunotherapy. Thus, understanding how tumor and stromal cells respond to hypoxia will allow for the design of innovative cancer therapies that can overcome these barriers. A better understanding of hypoxia-dependent mechanisms involved in the regulation of immune tolerance could lead to new strategies to enhance antitumor immunity. Therefore, discovery and validation of therapeutic targets derived from the hypoxic tumor microenvironment is of major importance. In this context, critical hypoxia-associated pathways are attractive targets for immunotherapy of cancer. In this review, we summarize current knowledge regarding the molecular mechanisms induced by tumor cell hypoxia with a special emphasis on therapeutic resistance and immune suppression. We emphasize mechanisms of manipulating hypoxic stress and its associated pathways, which may support the development of more durable and successful cancer immunotherapy approaches in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Macrophage activation and polarization
Martinez, F. O. (2008) · Frontiers in Bioscience · doi:10.2741/2692 · Cited by 3,160
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Self-citationInhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Self-citationShi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., & Chi, H. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110278 · Cited by 1,803
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
The effects of extracellular pH on immune function
Lardner, A. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.4.522 · Cited by 864
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 650
Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S., Van Ginderachter, J. A., Tamagnone, L., & Mazzone, M. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.007 · Cited by 629
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
Finlay, D. K., Rosenzweig, E., Sinclair, L. V., Feijoo-Carnero, C., Hukelmann, J. L., Rolf, J., Panteleyev, A. A., Okkenhaug, K., & Cantrell, D. A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112607 · Cited by 596
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560
Kobie, J. J., Shah, P. R., Yang, L., Rebhahn, J. A., Fowell, D. J., & Mosmann, T. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6780 · Cited by 466
Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P., & Kalinski, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2449 · Cited by 464
(1997) · PubMed · Cited by 433
Caldwell, C. C., Kojima, H., Lukashev, D., Armstrong, J., Farber, M., Apasov, S. G., & Sitkovsky, M. V. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6140 · Cited by 420
Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00207.2015 · Cited by 400
Self-citationAllavena, P., & Mantovani, A. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 384
Sceneay, J., Chow, M. T., Chen, A., Halse, H. M., Wong, C. S. F., Andrews, D. M., Sloan, E. K., Parker, B. S., Bowtell, D. D., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3873 · Cited by 364
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344
Self-citationCreating immune privilege: active local suppression that benefits friends, but protects foes
Mellor, A. L., & Munn, D. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2233 · Cited by 327
Cannibalism of Live Lymphocytes by Human Metastatic but Not Primary Melanoma Cells
Lugini, L., Matarrese, P., Tinari, A., Lozupone, F., Federici, C., Iessi, E., Gentile, M., Luciani, F., Parmiani, G., Rivoltini, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3204 · Cited by 290
Thiel, M., Chouker, A., Ohta, A., Jackson, E., Caldwell, C., Smith, P., Lukashev, D., Bittmann, I., & Sitkovsky, M. V. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030174 · Cited by 287
Hypoxia-Induced Gene Expression in Human Macrophages
Burke, B., Giannoudis, A., Corke, K. P., Gill, D., Wells, M., Ziegler-Heitbrock, L., & Lewis, C. E. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63483-9 · Cited by 286
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
Xia, Y., Choi, H.-K., & Lee, K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.033 · Cited by 278
IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer
Kryczek, I., Wu, K., Zhao, E., Wei, S., Vatan, L., Szeliga, W., Huang, E., Greenson, J., Chang, A., Roliński, J., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003251 · Cited by 264
Hypoxia controls CD4+CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α
Ben‐Shoshan, J., Maysel‐Auslender, S., Mor, A., Keren, G., & George, J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838318 · Cited by 260
Noman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256
Self-citationAnti-programmed cell death protein-1/ligand-1 therapy in different cancers
Homet Moreno, B., & Ribas, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.124 · Cited by 245
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
Cairns, R. A., Harris, I., McCracken, S., & Mak, T. W. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.012856 · Cited by 220
Payen, V. L., Porporato, P. E., Baselet, B., & Sonveaux, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2098-5 · Cited by 220
Sarkar, S., Germeraad, W. T. V., Rouschop, K. M. A., Steeghs, E. M. P., Gelder, M. V., Bos, G. M. J., & Wieten, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064835 · Cited by 215
Lukashev, D., Klebanov, B., Kojima, H., Grinberg, A., Ohta, A., Berenfeld, L., Wenger, R. H., Ohta, A., & Sitkovsky, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.4962 · Cited by 208
Immune-suppressive properties of the tumor microenvironment
Becker, J. C., Andersen, M. H., Schrama, D., & thor Straten, P. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1434-6 · Cited by 204
Lee, J. H., Elly, C., Park, Y., & Liu, Y.-C. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.016 · Cited by 203
Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells
Noman, M. Z., Buart, S., Romero, P., Ketari, S., Janji, B., Mari, B., Mami-Chouaib, F., & Chouaib, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1383 · Cited by 188
Self-citationPalazón, A., Martínez-Forero, I., Teijeira, A., Morales-Kastresana, A., Alfaro, C., Sanmamed, M. F., Perez-Gracia, J. L., Peñuelas, I., Hervás-Stubbs, S., Rouzaut, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0314 · Cited by 187
Thiel, M., Caldwell, C. C., Kreth, S., Kuboki, S., Chen, P., Smith, P., Ohta, A., Lentsch, A. B., Lukashev, D., & Sitkovsky, M. V. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000853 · Cited by 175
Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
Bellone, M., & Calcinotto, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00231 · Cited by 167
Nakamura, H., Makino, Y., Okamoto, K., Poellinger, L., Ohnuma, K., Morimoto, C., & Tanaka, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7592 · Cited by 158
Matrilysin [MMP-7] Expression Selects for Cells with Reduced Sensitivity to Apoptosis
Fingleton, B., Vargo-Gogola, T., Crawford, H. C., & Matrisian, L. M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900190 · Cited by 158
Nakagawa, Y., Negishi, Y., Shimizu, M., Takahashi, M., Ichikawa, M., & Takahashi, H. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.07.003 · Cited by 149
Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1α-Dependent Phenotype Switching
Widmer, D. S., Hoek, K. S., Cheng, P. F., Eichhoff, O. M., Biedermann, T., Raaijmakers, M. I. G., Hemmi, S., Dummer, R., & Levesque, M. P. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.115 · Cited by 148
The Tumor Microenvironment and Strategies to Improve Drug Distribution
Saggar, J. K., Yu, M., Tan, Q., & Tannock, I. F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00154 · Cited by 131
HER-2/ neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy
Scardino, A., Gross, D., Alves, P. M. S., Schultze, J. L., Graff‐Dubois, S., Faure, O., Tourdot, S., Chouaı̈b, S., Nadler, L. M., Lemonnier, F. A., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5900 · Cited by 120
Self-citationITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy
Messai, Y., Noman, M. Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., Baud, V., Viry, E., Billot, K., Nanbakhsh, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0303 · Cited by 119
Self-citationHypoxia and lineage specification of cell line-derived colorectal cancer stem cells
Yeung, T. M., Gandhi, S. C., & Bodmer, W. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014519107 · Cited by 118
HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Semenza, G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649402 · Cited by 116
Hasmim, M., Noman, M. Z., Messai, Y., Bordereaux, D., Gros, G., Baud, V., & Chouaïb, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302140 · Cited by 115
Self-citationImpact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics
Lin, Q., & Yun, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.12.12347 · Cited by 108
Tittarelli, A., Janji, B., Van Moer, K., Noman, M. Z., & Chouaib, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.651547 · Cited by 105
Self-citationHypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues
Lukashev, D. E., Ohta, A., & Sitkovsky, M. V. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9054-2 · Cited by 105
Noman, M. Z., Messai, Y., Carré, T., Akalay, I., Meron, M., Janji, B., Hasmim, M., & Chouaı̈b, S. (2011) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v31.i5.10 · Cited by 104
Self-citationLukashev, D. E., Caldwell, C. C., Ohta, A., Chen, P., & Sitkovsky, M. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104782200 · Cited by 99
Lin, S., Wan, S., Sun, L., Hu, J., Fang, D., Zhao, R., Yuan, S., & Zhang, L. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02259.x · Cited by 95
Autophagic degradation of GZMB/granzyme B
Viry, E., Bagińska, J., Berchem, G., Noman, M. Z., Medves, S., Chouaı̈b, S., & Janji, B. (2013) · Autophagy · doi:10.4161/auto.26924 · Cited by 92
Self-citationIn vivo T Cell Activation in Lymphoid Tissues is Inhibited in the Oxygen-Poor Microenvironment
Ohta, A., Diwanji, R., Kini, R., Subramanian, M., Ohta, A., & Sitkovsky, M. V. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00027 · Cited by 90
Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
Sceneay, J., Parker, B. S., Smyth, M. J., & Möller, A. (2012) · OncoImmunology · doi:10.4161/onci.22355 · Cited by 80
Hamaï, A., Benlalam, H., Meslin, F., Hasmim, M., Carré, T., Akalay, I., Janji, B., Berchem, G., Noman, M. Z., & Chouaïb, S. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01401.x · Cited by 77
Self-citationTargeting hypoxia at the forefront of anticancer immune responses
Noman, M. Z., & Chouaib, S. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954463 · Cited by 70
Self-citationYamada, N., Yamanegi, K., Ohyama, H., Hata, M., Nakasho, K., Futani, H., Okamura, H., & Terada, N. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1630 · Cited by 69
Hypoxia-induced autophagy: A new player in cancer immunotherapy?
Noman, M. Z., Janji, B., Berchem, G., Mami‐Chouaib, F., & Chouaïb, S. (2012) · Autophagy · doi:10.4161/auto.19572 · Cited by 68
Self-citationRobbins, J. R., Lee, S. M., Filipovich, A. H., Szigligeti, P., Neumeier, L., Petrovic, M., & Conforti, L. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.081893 · Cited by 67
Redegeld, F. A., Filippini, A., & Sitkovsky, M. V. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.10.3638 · Cited by 66
Zhang, J., Han, C., Dai, H., Hou, J., Dong, Y., Cui, X., Xu, L., Zhang, M., & Xia, Q. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121248 · Cited by 65
Tan, S., Zhou, F., Nielsen, V. G., Wang, Z., Gladson, C. L., & Parks, D. A. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199806000-00002 · Cited by 57
Kotsakis, A. P., Vetsika, E., Christou, S., Hatzidaki, D., Vardakis, N., Aggouraki, D., Konsolakis, G., Georgoulias, V., Christophyllakis, C., Cordopatis, P. A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr396 · Cited by 53
Self-citationRegulation of T-cell functions by l-lactate
Dröge, W., Roth, S., Altmann, A., & Mihm, S. (1987) · Cellular Immunology · doi:10.1016/0008-8749(87)90223-1 · Cited by 49
The autophagy sensor ITPR1 protects renal carcinoma cells from NK-mediated killing
Messai, Y., Noman, M. Z., Janji, B., Hasmim, M., Escudier, B. J., & Chouaı̈b, S. (2015) · Autophagy · doi:10.1080/15548627.2015.1017194 · Cited by 44
Self-citationNoman, M. Z., Janji, B., Berchem, G., & Chouaïb, S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.026 · Cited by 34
Self-citationRatner, S. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.7.612 · Cited by 26
Terry, S., & Chouaı̈b, S. (2015) · Oncoscience · doi:10.18632/oncoscience.226 · Cited by 23
HIF2a inhibitors for the treatment of VHL disease
Metelo, A. M., Noonan, H. R., & Iliopoulos, O. (2015) · Oncotarget · doi:10.18632/oncotarget.4564 · Cited by 21
HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysis
Messai, Y., Noman, M. Z., Hasmim, M., Escudier, B. J., & Chouaı̈b, S. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985951 · Cited by 19
Self-citationDamage control by hypoxia-inhibited AK
Sitkovsky, M. V. (2008) · Blood · doi:10.1182/blood-2008-03-143990 · Cited by 17
Cytotoxic T cells – Stroma interactions
Noman, M. Z., Benlalam, H., Hasmim, M., & Chouaïb, S. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2010.1295 · Cited by 10
Self-citationWolter, F., Glässner, A., Krämer, B., Kokordelis, P., Finnemann, C., Kaczmarek, D. J., Goeser, F., Lutz, P. L., Nischalke, H. D., Strassburg, C. P., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.008 · Cited by 10
Carving out its niche: A role for carbonic anhydrase IX in pre-metastatic niche development
Chafe, S. C., & Dedhar, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1048955 · Cited by 10
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
Metadata
- Authors
- Chouaib, S., Noman, M. Z., Kosmatopoulos, K., & Curran, M. A.
- Venue
- Oncogene
- Published
- 2016-06-27
- Volume
- 36
- Issue
- 4
- Pages
- 439-445
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2463432841
- Cited by
- 365
- References
- 99
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.